SCHEMBL20564281

SCHEMBL20564281

COc1ccc(COc2nc(SC)nc(-c3cnn(C(C)C)c3)c2C(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 2/20 0.40
KDM5A P29375 1/20 0.38
CSF1R P07333 4/20 0.36
LRRK2 Q5S007 4/20 0.35
JAK2 O60674 4/20 0.35
FLT3 P36888 4/20 0.35
TYK2 P29597 3/20 0.35
JAK1 P23458 2/20 0.35
JAK3 P52333 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
FGFR1 P11362 3/20 0.35
FGFR2 P21802 3/20 0.35
FGFR3 P22607 3/20 0.35
FGFR4 P22455 2/20 0.34
KDR P35968 2/20 0.34
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20958117 0.83 KDM5B (0.41) KDM5BKDM5ACSF1RLRRK2JAK2
SCHEMBL20565461 0.81 KDM5B (0.38) KDM5BKDM5ACSF1RLRRK2JAK2
SCHEMBL20564425 0.76 LMNA (0.52) L3MBTL1LMNAMEN1ALDH1A1MAPT
SCHEMBL20565319 0.75 CSF1R (0.48) KDM5BKDM5ACSF1RFGFR1FGFR2
SCHEMBL20564181 0.70 CSF1R (0.43) KDM5BKDM5ACSF1RLMNAALDH1A1
SCHEMBL13322685 0.67 KDR (0.47) FLT3FGFR1FGFR2FGFR3FGFR4
SCHEMBL12286477 0.66 CNR1 (0.41) L3MBTL1LMNAMEN1ALDH1A1MAPT
SCHEMBL20929092 0.65 PPARG (0.59) KDM5BKDM5AL3MBTL1MEN1ALDH1A1
SCHEMBL15634008 0.64 HTT (0.50) CSF1RL3MBTL1LMNAMEN1ALDH1A1
SCHEMBL20564303 0.64 MAOB (0.43) LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
WO-2018213777-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE KDM5A, KDM5B, KDM5C KDM5B 2/4885KDM5A 1/4885CSF1R 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.